Institut de Génétique et de Biologie Moléculaire et Cellulaire, Institut National de Santé et de Recherche Médicale (INSERM) U964, Centre National de Recherche Scientifique (CNRS) UMR1704, Université de Strasbourg, 67404 Illkirch, France.
Hum Reprod. 2013 Apr;28(4):1054-61. doi: 10.1093/humrep/det005. Epub 2013 Feb 14.
Does DPY19L2 status influence intracytoplasmic sperm injection (ICSI) outcomes with or without assisted oocyte activation (AOA)?
DPY19L2 mutations have no major impact on ICSI outcomes in globozoospermic patients.
Globozoospermia is a rare and severe teratozoospermia characterized by round-headed spermatozoa lacking an acrosome. Recently, it has been shown that DPY19L2 mutations can be found in a vast majority of, but not all, globozoospermic patients (66.7%). These patients suffer from primary infertility due to a sperm-related oocyte activation deficiency secondary to the absence of an acrosome that can be overcome by the application of AOA.
STUDY DESIGN, SIZE, DURATION: Cohort study, retrospective, 34 patients, 83 cycles.
MATERIALS, SETTING, METHODS: Clinical and biologic data were collected from 29 patients mutated for DPY19L2 and 5 non-mutated patients. In total, 35 ICSI cycles using AOA and 48 conventional ICSI cycles were included in the analysis. Patients were divided into groups according to whether or not they were mutated for DPY19L2 and whether or not they received AOA.
Regardless of the presence of a DPY19L2 mutation, the fertilization rates with AOA are restored to normal when compared with conventional ICSI in our cohort of globozoospermic patients. Also, when performing ICSI plus AOA, both mutated and non-mutated cases have similar positive hCG rates, ongoing pregnancy rates and live birth rates per transfer. On the contrary, the fertilization rate in globozoospermic patients using conventional ICSI is correlated with the presence of a DPY19L2 mutation, with slightly better, although still very low, fertilization rates in patients carrying a DPY19L2 mutation. Nevertheless, when performing conventional ICSI, both mutated and non-mutated cases have similar very low positive hCG rates, ongoing pregnancy rates and live birth rates per transfer.
A limitation of this study is the low number of included non-mutated cases.
We propose a pathway for the clinical management of globozoospermic patients depending on the phenotype that includes several diagnostic and therapeutic steps.
STUDY FUNDING/COMPETING INTEREST(S): None.
DPY19L2 状态是否会影响卵胞浆内单精子注射(ICSI)的结果,无论是否辅助卵母细胞激活(AOA)?
DPY19L2 突变对圆头精子症患者的 ICSI 结果没有重大影响。
圆头精子症是一种罕见且严重的畸形精子症,其特征是精子头部呈圆形,缺乏顶体。最近,研究表明,DPY19L2 突变可在绝大多数(但不是全部)圆头精子症患者中发现(66.7%)。这些患者因缺乏顶体而导致精子相关的卵母细胞激活缺陷导致原发性不育,而顶体的缺乏可以通过应用 AOA 来克服。
研究设计、大小、持续时间:队列研究,回顾性,34 名患者,83 个周期。
材料、设置、方法:从 29 名 DPY19L2 突变患者和 5 名非突变患者中收集临床和生物学数据。总共分析了 35 个使用 AOA 的 ICSI 周期和 48 个常规 ICSI 周期。根据是否存在 DPY19L2 突变以及是否接受 AOA,将患者分为两组。
无论是否存在 DPY19L2 突变,与常规 ICSI 相比,在我们的圆头精子症患者队列中,使用 AOA 的受精率恢复正常。此外,在进行 ICSI 加 AOA 时,突变和非突变病例的 hCG 阳性率、持续妊娠率和每转移的活产率相似。相反,在使用常规 ICSI 的圆头精子症患者中,受精率与 DPY19L2 突变的存在相关,携带 DPY19L2 突变的患者的受精率略高,但仍然非常低。然而,在进行常规 ICSI 时,突变和非突变病例的 hCG 阳性率、持续妊娠率和每转移的活产率相似,均非常低。
本研究的一个局限性是纳入的非突变病例数量较少。
我们提出了一种根据包括几个诊断和治疗步骤的表型对圆头精子症患者进行临床管理的途径。
研究资金/竞争利益:无。